v3.26.1
Segment Information - Schedule of Significant Segment Expenses (Details) - USD ($)
$ in Thousands
12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2024
Segment Information [Line Items]      
Revenue $ 8,260 $ 29,053 $ 32,713
Less:      
Cost of revenues 1,285 911 1,599
Research and development expense 681,812 550,413 439,909
Share-based compensation 346,165 289,029 199,627
Acquired in-process research and development 0 0 26,450
General and administrative expenses 610,466 591,410 416,133
Gain on sale of Telavant net assets 0 (110,387) (5,348,410)
Gain on litigation settlement (770,235) 0 0
Change in fair value of investments (105,046) (55,186) 47,973
Change in fair value of liability instruments 47,704 (15,756) 46,838
Gain on deconsolidation of subsidiaries (11,027) (3,108) (32,772)
Interest income (178,109) (258,375) (146,425)
Other (income) expense, net (4,012) 10,721 13,562
Income tax expense 133,329 48,174 21,503
(Income) loss from discontinued operations, net of tax 0 (373,030) 315,147
Net (loss) income (397,907) (356,734) 4,231,206
Reportable Segment      
Segment Information [Line Items]      
Revenue 8,260 29,053 32,713
Less:      
Cost of revenues 1,285 911 1,599
Acquired in-process research and development 0 0 26,450
Gain on sale of Telavant net assets 0 (110,387) (5,348,410)
Gain on litigation settlement (770,235) 0 0
Change in fair value of investments (105,046) (55,186) 47,973
Change in fair value of liability instruments 47,704 (15,756) 46,838
Gain on deconsolidation of subsidiaries (11,027) (3,108) (32,772)
Interest income (178,109) (258,375) (146,425)
Other (income) expense, net (4,012) 10,721 13,562
Income tax expense 133,329 48,174 21,503
(Income) loss from discontinued operations, net of tax 0 (373,030) 315,147
Net (loss) income (397,907) (356,734) 4,231,206
Research and development share-based compensation      
Less:      
Share-based compensation 47,867 39,780 32,400
Research and development share-based compensation | Reportable Segment      
Less:      
Share-based compensation 47,867 39,780 32,400
Research and development personnel-related expenses | Reportable Segment      
Less:      
Research and development expense 167,790 146,162 123,283
Other research and development expenses | Reportable Segment      
Less:      
Research and development expense 37,285 36,717 35,010
General and administrative share-based compensation      
Less:      
Share-based compensation 298,298 239,505 154,873
General and administrative share-based compensation | Reportable Segment      
Less:      
Share-based compensation 298,298 239,505 154,873
General and administrative personnel-related expenses | Reportable Segment      
Less:      
General and administrative expenses 135,850 205,737 126,163
Other general and administrative expenses | Reportable Segment      
Less:      
General and administrative expenses 176,318 146,168 135,097
Anti-FcRn franchise—endocrine diseases | Reportable Segment      
Less:      
Research and development expense 90,359 63,073 33,205
Anti-FcRn franchise—neurological diseases | Reportable Segment      
Less:      
Research and development expense 82,515 93,224 41,060
Anti-FcRn franchise—rheumatology diseases | Reportable Segment      
Less:      
Research and development expense 48,813 23,897 0
Anti-FcRn franchise—dermatology diseases | Reportable Segment      
Less:      
Research and development expense 20,264 15,633 0
Anti-FcRn franchise—other clinical and nonclinical | Reportable Segment      
Less:      
Research and development expense 3,367 9,327 39,811
Anti-FcRn franchise—contractual costs related to batoclimab program discontinuation | Reportable Segment      
Less:      
Research and development expense 38,952 0 0
Brepocitinib | Reportable Segment      
Less:      
Research and development expense 60,272 45,125 38,563
Mosliciguat | Reportable Segment      
Less:      
Research and development expense 36,077 19,746 4,307
Other development and discovery programs | Reportable Segment      
Less:      
Research and development expense $ 48,251 $ 57,729 $ 92,270